Table 2 Clinical and histopathological variables in patients stratified by differences in Ki67 and PSA immunostaining

From: Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome

  PSA high/Ki67 low PSA high/Ki67 high PSA low/Ki67 low PSA low/Ki67 high
  (n = 141, 42%) (n = 17, 5%) (n = 105, 32%) (n = 68, 20%)
Clinical markers     
 Age 74 (69; 78) 75 (71; 79) 74 (69; 78) 75 (69; 82)
 GS    ***a ***a,***b
  4–6 95 (67) 9 (53) 37 (35) 7 (10)
  7 29 (21) 3 (18) 23 (22) 7 (10)
  8–10 17 (12) 5 (29) 45 (43) 54 (79)
 Tumor stage   *a ***a ***a, **b
  T1 94 (67) 7 (41) 38 (36) 11 (16)
  T2 35 (25) 5 (29) 31 (30) 20 (29)
  T3–4 11 (7.8) 5 (29) 33 (31) 34 (50)
  x 1 (0.7) 0 3 (3) 3 (4)
 M stage   *a **a ***a,**b
  0 100 (71) 11 (65) 73 (70) 35 (51)
  1 3 (2) 2 (12) 13 (12) 23 (34)
  x 38 (27) 4 (24) 19 (18) 10 (15)
 Cancer (%) 10 (7.5; 45) 30 (10;70) 60 (20; 85)***a 88 (50; 95)***a,***b
 PC death (%) 26 (18) 5 (29) 51 (49)***a 50 (74)***a,**b
Tumor markers
  pEGF-R score (13) (epithelial) 3.1 (2.4; 3.6) (n = 110) 3.6 (3.1; 3.9) (n = 8) 3.3 (2.8; 3.6) (n = 83) 3.6 (3.3; 4.0) ***a,**b (n = 45)
  ErbB2 score (28) (epithelial) 2.8 (2.0; 3.0) (n = 126) 3.0 (2.7; 3.8)**a (n = 14) 3.0 (2.3; 3.8)**a (n = 99) 3.0 (3.0; 4.0) ***a,*b (n = 63)
  ERG (35)     
   negative 105 (79.5) 10 (62.5) 43 (44.3) 21 (32.3)
   positive (epithelial) 27 (20.5) 6 (37.5) 54 (55.7) ***a 44 (67.7) ***a
  pAkt score (29) (epithelial) 2.6 (2.2; 2.9) (n = 109) 2.8 (2.5; 3.3) (n = 12) 2.8 (2.4; 3.1)**a (n = 81) 3.1 (2.8; 3.6) ***a,***b (n = 49)
  Ki67 (%) (12, 15) (epithelial) 1.4 (0.4; 2.7) (n = 141) 8.8 (7.5; 13.6) ***a,***b (n = 17) 2.5 (1.2; 3.6)***a (n = 105) 10.9 (7.2; 15.6) ***a,***b (n = 68)
  Vascular density (%) (12, 15) 11 (8; 16) (n = 138) 16 (9; 19) (n = 17) 15 (10; 21)**a (n = 101) 19 (12; 24)***a,*b (n = 68)
  Hyaluronic acid score (32) (stroma) 7.1 (4.6; 9.0) (n = 139) 9 (6; 11)*a (n = 17) 7.8 (5.6; 9.8)*a (n = 105) 8.6 (6.2; 11.3)***a (n = 67)
  Mast cell density (%) (343) 13 (9; 16) (n = 134) 14 (7; 17) (n = 16) 12 (8; 16) (n = 100) 8 (4; 13)***a,***b (n = 65)
  Androgen receptor (%) (30) (stroma) 50 (39; 65) (n = 136) 52 (22; 67) (n = 16) 48 (28; 64) (n = 103) 37 (14; 55)***a,**b (n = 67)
  Caveolin-1 score (31) (stroma) 3.0 (2.8; 3.4) (n = 139) 3.1 (2.9, 3.4) (n = 16) 3.0 (2.8; 3.3)*a (n = 101) 2.8 (2.6; 3.1) ***a,**b (n = 64)
  CD163 (%) (33) 16 (11; 22) (n = 87) 21 (12; 30) (n = 4) 19 (16; 28)***a (n = 53) 19 (14; 26) (n = 29)
TINT markers
  Ki67 (%) (12, 15) (epithelial) 0.2 (0; 1.2) (n = 138) 0 (0; 1.3) (n = 17) 0.3 (0; 1.2) (n = 95) 0.5 (0; 2.5) (n = 57)
  pEGF-R score (13) (epithelial) 3.0 (1.8; 3.5) (n = 111) 2.7 (2.1; 3.5) (n = 9) 3.3 (2.5; 3.8) **a (n = 79) 3.5 (3; 3.9) **a (n = 40)
  pAKT score (29) (epithelial) 2.0 (1.5; 2.5) (n = 92) 2.0 (1.4; 2.3) (n = 11) 2.3 (1.6; 2.8) (n = 56) 2.4 (1.5; 2.8) (n = 34)
  ERG (35)     
   negative 117 (92.9) 13 (76.5) 75 (85.2) 40 (83.3)
   positive (epithelial) 9 (7.1) 4 (23.5)*a 13 (14.8) 8 (16.7) *a
  Hyaluronic acid score (32) (stroma) 6.3 (4.3; 8.0) (n = 135) 5.5 (3.8; 8.1) (n = 17) 6.5 (5.0; 9.0) (n = 99) 7 (5; 9) (n = 59)
  Mast cell density (%) (34) 12 (8; 15) n = 130 12 (9; 16) (n = 17) 14 (10; 20) **a (n = 91) 14 (11; 20) **a (n = 53)